In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...

Initially, ZIVO and its partner have executed two agreements that will govern independent studies designed to validate and expand the use of ZIVO's proprietary actives as immune-enhancing biologics to ...

Title: Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal Regulation, and ...

The virus was selected for its well-established in vivo ... release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the ...

Summary: This preclinical study evaluated icovamenib's direct effects on ex vivo human myotube cultures and the effects of icovamenib in combination with low-dose semaglutide in an in vivo rodent ...

INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare company focused on the fertility sector, today announced it has received a notice of allowance on a new patent for ...

In ex vivo cultures of iPSC-derived 3D-engineered human myotubes, ... and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Dr. Gretchen Collins, medical director and Reproductive Endocrinologist and Infertility specialist at Wisconsin Fertility Institute, is now further licensed in Illinois, Minnesota, Iowa, Montana, ...